Bioliberty closed a US$3.3 million Series A extension round. The company develops rehabilitation technology that supports therapy and assessment. The new round adds to US$10.2 million raised through its Pre-Series A and Series A.
New investors
The extension brings TGH Ventures, Ballad Ventures, Whiterock, and 25m Health into Bioliberty. They all joined the company as new investors. The investors are supporting Bioliberty's next stage of growth.
Rehabilitation focus
Bioliberty works in the rehabilitation technology sector. Its technology supports physical and occupational therapists during rehabilitation. The tools are designed for therapy and assessment.
Product plans
The company plans to extend its technology into the home. This would allow rehabilitation to continue after a patient leaves a facility. It also plans to connect rehabilitation data across care settings.
The company will develop additional AI capabilities designed for therapy and assessment. These tools are meant for physical and occupational therapists. Providers should gain greater insight into patient recovery.